What is Nanolive?
Founded in 2013 and headquartered in Tolochenaz, Switzerland, Nanolive is at the forefront of biotechnology, providing advanced research products designed to simplify and enhance live cell imaging and analysis. The company's solutions are crucial for researchers seeking to gain deeper insights into cellular processes without complex staining or manipulation. Nanolive's technology addresses a critical need in the life sciences sector for efficient and non-invasive cellular observation, positioning it as a key player in the field.
How much funding has Nanolive raised?
Nanolive has raised a total of $23.3M across 3 funding rounds:
Private Equity
$2.8M
Unspecified
$514K
Series C
$20M
Private Equity (2014): $2.8M, investors not publicly disclosed
Unspecified (2016): $514K led by Swisscom
Series C (2022): $20M supported by Swisscom Ventures and Taiwania Capital
Key Investors in Nanolive
Swisscom
Swisscom, a prominent Swiss telecommunications provider, has invested in Nanolive. Their involvement suggests a strategic interest in the intersection of technology and biotechnology, potentially leveraging Nanolive's data-intensive imaging solutions.
Swisscom Ventures
Swisscom Ventures, the venture capital arm of Swisscom, has participated in Nanolive's funding rounds. This indicates a focus on supporting innovative technology companies with high growth potential.
Taiwania Capital
Taiwania Capital, a venture capital firm with a focus on early-stage companies in areas like AI, IoT, and next-gen semiconductors, has backed Nanolive. Their investment highlights Nanolive's technological innovation and potential for disruption in the biotech sector.
What's next for Nanolive?
With its recent major strategic investment, Nanolive is poised for accelerated expansion and further development of its cutting-edge imaging technologies. This capital will likely fuel advancements in product innovation, market penetration, and strategic partnerships within the biotechnology and pharmaceutical industries. The company's focus on streamlining live cell analysis suggests a future where complex biological research becomes more accessible and efficient, potentially leading to faster discoveries in drug development and disease understanding.
See full Nanolive company page
